AroCell AB announces today that a second abstract has been accepted by ISOBM (International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany November 24-27, 2018.
The study, entitled “Molecular forms of serum thymidine kinase 1 in hematological malignancies determined with the AroCell TK 210TM ELISA,” confirms the importance and significance of using AroCell’s proprietary sample dilution buffer included in TK 210 ELISA for pre-treatment of samples. The sample preparation step is clearly improving the diagnostic value when quantifying the concentration of thymidine kinase in serum samples from subjects with hematological malignancies.
“These results show that AroCell’s TK 210 ELISA technique reduces the unspecific detection of TK1 in samples from healthy blood donors, thus improving the diagnostic value of the test. We are confirming the improved discrimination between hematological malignancies and healthy blood donors using the AroCell’s sample preparation method,” says Professor Eriksson, head of R&D at AroCell.
In addition to the poster presentation above, the company will, in an oral presentation session at ISOBM, present results from a performance evaluation of TK 210 ELISA and activity-based methods, as earlier communicated.
These two presentations comfirm that TK 210 ELISA is a valuable tool in the management of hematological malignancies, as well as of breast cancer as, previously described (Tumor Biology, 2016). The test is sensitive, specific and robust. The ELISA format is well suited for implementation on automated ELISA platforms which are already installed at many routine clinical laboratories.
For more information:
Johan von Heijne, Acting CEO
Telephone: +46-705-95 15 10
AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, at 08.40 on October 9,2018.
AroCell AB (AROC) is a Swedish company that is developing standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. The AroCell share (AROC) is listed on Nasdaq First North with Redeye AB as Certified Adviser.
For more information, please see www.arocell.com.